Biotech Protalix, Chiesi edge close to potential Fabry disease approval

Biotech Protalix, Chiesi edge close to potential Fabry disease approval

Submitted by admin on May 28, 2020 - 10:53am
Source: 
Fierce Biotech
News Tags: 
Protalix BioTherapeutics
Chiesi
Fabry disease
pegunigalsidase alfa
Headline: 
Biotech Protalix, Chiesi edge close to potential Fabry disease approval
snippet: 

Israeli biotech Protalix BioTherapeutics and partner Chiesi have sent off their Biologics License Application for rare disease hopeful pegunigalsidase alfa to the FDA.

Do Not Allow Advertisers to Use My Personal information